These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

64 related articles for article (PubMed ID: 15370619)

  • 1. Complete sustained regression of extensive psoriasis with cetuximab combination chemotherapy.
    Trivin F; Boucher E; Raoul JL
    Acta Oncol; 2004; 43(6):592-3. PubMed ID: 15370619
    [No Abstract]   [Full Text] [Related]  

  • 2. Complete remission of psoriasis following bevacizumab therapy for colon cancer.
    Akman A; Yilmaz E; Mutlu H; Ozdogan M
    Clin Exp Dermatol; 2009 Jul; 34(5):e202-4. PubMed ID: 19077094
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cetuximab and panitumumab in a patient with colon cancer and concomitant chronic skin disease: a potential beneficial effect on psoriasis vulgaris.
    Okamoto K; Maeda H; Shiga T; Shiga M; Dabanaka K; Hanazaki K; Kobayashi M
    World J Gastroenterol; 2015 Mar; 21(12):3746-9. PubMed ID: 25834345
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Cetuximab. A monoclonal antibody against the EGF receptor].
    Wasielewski S
    Med Monatsschr Pharm; 2004 Sep; 27(9):292-4. PubMed ID: 15490614
    [No Abstract]   [Full Text] [Related]  

  • 5. The biological properties of cetuximab.
    Vincenzi B; Schiavon G; Silletta M; Santini D; Tonini G
    Crit Rev Oncol Hematol; 2008 Nov; 68(2):93-106. PubMed ID: 18676156
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cetuximab in advanced non-small cell lung cancer.
    Govindan R
    Clin Cancer Res; 2004 Jun; 10(12 Pt 2):4241s-4244s. PubMed ID: 15217966
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Psoriasis induced by cetuximab: a paradoxical adverse effect.
    Mas-Vidal A; Coto-Segura P; Galache-Osuna C; Santos-Juanes J
    Australas J Dermatol; 2011 Feb; 52(1):56-8. PubMed ID: 21332695
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antitumor effect of FP3 in combination with cetuximab on patient-derived tumor tissue xenograft models of primary colon carcinoma and related lymphatic and hepatic metastases.
    Dong X; Jin K; Hu X; Du F; Lan H; Han N; Ma Z; Xie B; Cui B; Teng L; Cao F
    Int J Mol Med; 2012 Jul; 30(1):126-32. PubMed ID: 22505231
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Papulo-pustular eruption during cetuximab treatment.
    Satta R; Cuccuru MA; Pirodda C; Cottoni F
    G Ital Dermatol Venereol; 2008 Feb; 143(1):87-8. PubMed ID: 18833056
    [No Abstract]   [Full Text] [Related]  

  • 10. Anti-EGFR therapy update: clinical experience and adverse event insights.
    Harari PM
    Oncology (Williston Park); 2006 Apr; 20(5 Suppl 2):3-4. PubMed ID: 16736977
    [No Abstract]   [Full Text] [Related]  

  • 11. Synergistic antitumor effects of combined epidermal growth factor receptor and vascular endothelial growth factor receptor-2 targeted therapy.
    Tonra JR; Deevi DS; Corcoran E; Li H; Wang S; Carrick FE; Hicklin DJ
    Clin Cancer Res; 2006 Apr; 12(7 Pt 1):2197-207. PubMed ID: 16609035
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Signaling multiplex of the epidermal growth factor receptor.
    Higa GM
    Expert Rev Anticancer Ther; 2004 Dec; 4(6):1145-56. PubMed ID: 15606339
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase 1 escalating single-dose and weekly fixed-dose study of cetuximab: pharmacokinetic and pharmacodynamic rationale for dosing.
    Fracasso PM; Burris H; Arquette MA; Govindan R; Gao F; Wright LP; Goodner SA; Greco FA; Jones SF; Willcut N; Chodkiewicz C; Pathak A; Springett GM; Simon GR; Sullivan DM; Marcelpoil R; Mayfield SD; Mauro D; Garrett CR
    Clin Cancer Res; 2007 Feb; 13(3):986-93. PubMed ID: 17289894
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel toll-like receptor 9 agonist induces epidermal growth factor receptor (EGFR) inhibition and synergistic antitumor activity with EGFR inhibitors.
    Damiano V; Caputo R; Bianco R; D'Armiento FP; Leonardi A; De Placido S; Bianco AR; Agrawal S; Ciardiello F; Tortora G
    Clin Cancer Res; 2006 Jan; 12(2):577-83. PubMed ID: 16428503
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Drug Insight: cetuximab in the treatment of recurrent and metastatic squamous cell carcinoma of the head and neck.
    Bernier J
    Nat Clin Pract Oncol; 2008 Dec; 5(12):705-13. PubMed ID: 18825142
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cetuximab, its clinical use and future perspectives.
    Rivera F; Vega-Villegas ME; López-Brea MF
    Anticancer Drugs; 2008 Feb; 19(2):99-113. PubMed ID: 18176106
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fatal toxic epidermal necrolysis associated with cetuximab in a patient with colon cancer.
    Lin WL; Lin WC; Yang JY; Chang YC; Ho HC; Yang LC; Yang CH; Hung SI; Chung WH
    J Clin Oncol; 2008 Jun; 26(16):2779-80. PubMed ID: 18509187
    [No Abstract]   [Full Text] [Related]  

  • 18. Cetuximab: an epidermal growth factor receptor monoclonal antibody for the treatment of colorectal cancer.
    Wong SF
    Clin Ther; 2005 Jun; 27(6):684-94. PubMed ID: 16117976
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Potential of ErbB4 antibodies for cancer therapy.
    Hollmén M; Elenius K
    Future Oncol; 2010 Jan; 6(1):37-53. PubMed ID: 20021208
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vaccination with cetuximab mimotopes and biological properties of induced anti-epidermal growth factor receptor antibodies.
    Riemer AB; Kurz H; Klinger M; Scheiner O; Zielinski CC; Jensen-Jarolim E
    J Natl Cancer Inst; 2005 Nov; 97(22):1663-70. PubMed ID: 16288119
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.